Abstract

Ambiguous data on both terminology, diagnostics, and treatment of testosterone deficiency in men prompted us to attempt a critical analysis of existing knowledge on this subject. Current guidelines of both American and European Association of Urology (AUA, EUA) define testosterone therapy as effective and safe. However, media reports and some scientific reports indicating negative effects of the abovementioned therapy arouse aversion to its use by doctors and potential patients for fear of developing prostate cancer or cardiovascular incidents. The peak of scepticism about testosterone therapy was observed after the publication in 2013 and 2014, respectively, two retrospective data analysis on this topic, which resulted in the discontinuation of therapy in many patients with long histories of benefits from testosterone therapy. In addition, in many men with indications for testosterone therapy, this treatment was not used for fear of patient safety. However, the latest data on these concerns do not confirm any negative effects. More than 100 recently published scientific studies have shown the beneficial effects of testosterone therapy on many aspects of health. The American Society of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) have jointly developed their own literature assessment, stating that there is no convincing evidence that testosterone therapy increases the risk of cardiovascular incidents. The same conclusions can be drawn from the current EAU and AUA guidelines.

References

• 1. Almeida O.P., Yeap B.B., Hankey G.J., Jamrozik K., Flicker L.: Lowfree testosterone concentration as a potentially treatable cause ofdepressive symptoms in older men. Arch. Gen. Psychiatry, 2008;65: 283–289
  Google Scholar
• 2. Araujo A.B., O’Donnell A.B., Brambilla D.J., Simpson W.B., LongcopeC., Matsumoto A.M., McKinlay J.B.: Prevalence and incidenceof androgen deficiency in middle-aged and older men: Estimatesfrom the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab.,2004; 89: 5920–5926
  Google Scholar
• 3. Baillargeon J., Urban R.J., Morgentaler A., Glueck C.J., BaillargeonG., Sharma G., Kuo Y.F..: Risk of venous thromboembolism in menreceiving testosterone therapy. Mayo Clin. Proc., 2015; 90: 1038–1045
  Google Scholar
• 4. Caminiti G., Volterrani M., Iellamo F., Marazzi G., Massaro R.,Miceli M., Mammi C., Piepoli M., Fini M., Rosano G.M.: Effect oflong-acting testosterone treatment on functional exercise capacity,skeletal muscle performance, insulin resistance, and baroreflexsensitivity in elderly patients with chronic heart failure a doubleblind,placebo-controlled, randomized study. J. Am. Coll. Cardiol.,2009; 54: 919–927
  Google Scholar
• 5. Chao J.K., Hwang T.I., Ma M.C., Kuo W.H., Liu J.H., Chen Y.P., LinY.C.: A survey of obesity and erectile dysfunction of men conscriptedinto the military in Taiwan. J. Sex. Med., 2011; 8: 1156–1163
  Google Scholar
• 6. Corona G., Mannucci E., Fisher A.D., Lotti F., Petrone L., BalerciaG., Bandini E., Forti G., Maggi M.: Low levels of androgens inmen with erectile dysfunction and obesity. J. Sex. Med., 2008; 5:2454–2463
  Google Scholar
• 7. Corona G., Rastrelli G., Monami M., Melani C., Balzi D., Sforza A.,Forti G., Mannucci E., Maggi M.: Body mass index regulates hypogonadism-associated CV risk: Results from a cohort of subjects witherectile dysfunction. J. Sex. Med., 2011; 8: 2098–2105
  Google Scholar
• 8. Coviello A.D., Matsumoto A.M., Bremner W.J., Herbst K.L., AmoryJ.K., Anawalt B.D., Sutton P.R., Wright W.W., Brown T.R., Yan X.,Zirkin B.R., Jarow J.P.: Low-dose human chorionic gonadotropinmaintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J. Clin. Endocrinol.Metab., 2005; 90: 2595–2602
  Google Scholar
• 9. Crum-Cianflone N.F., Bavaro M., Hale B., Amling C., Truett A.,Brandt C., Pope B., Furtek K., Medina S., Wallace M.R.: Erectile dysfunctionand hypogonadism among men with HIV. AIDS PatientCare STDS, 2007; 21: 9–19
  Google Scholar
• 10. Dohle G.R., Arver S., Bettocchi C., Jones T.H., Kliesch S.: Europeanassociation of urology guidelines on male hypogonadism: The 2018 update. https://uroweb.org/guideline/male-hypogonadism/(05.02.2020)
  Google Scholar
• 11. Finkle W.D., Greenland S., Ridgeway G.K., Adams J.L., FrascoM.A., Cook M.B., Fraumeni J.F.Jr, Hoover R.N.: Increased risk of nonfatalmyocardial infarction following testosterone therapy prescriptionin men. PLoS One, 2014; 9: e85805
  Google Scholar
• 12. Ford A.H., Yeap B.B., Flicker L., Hankey G.J., Chubb S.A., HandelsmanD.J., Golledge J., Almeida O.P.: Prospective longitudinalstudy of testosterone and incident depression in older men: TheHealth In Men Study. Psychoneuroendocrinology, 2016; 64: 57–65
  Google Scholar
• 13. Francomano D., Greco E.A., Lenzi A., Aversa A.: CAG repeattesting of androgen receptor polymorphism: Is this necessary forthe best clinical management of hypogonadism? J. Sex. Med., 2013;10: 2373–2381
  Google Scholar
• 14. Garvey W.T., Mechanick J.I., Brett E.M., Garber A.J., Hurley D.L.,Jastreboff A.M., Nadolsky K., Pessah-Pollack R., Plodkowski R., Reviewersof the AACE/ACE Obesity Clinical Practice Guidelines: Associationof Clinical Endocrinologists and American College of EndocrinologyComprehensive Clinical Practice Guidelines for MedicalCare of Patients with Obesity. Endocr. Pract., 2016; 22: 1–203
  Google Scholar
• 15. Gianatti E.J., Dupuis P., Hoermann R., Zajac J.D., Grossmann M.:Effect of testosterone treatment on constitutional and sexual symptomsin men with type 2 diabetes in a randomized, placebo-controlledclinical trial. J. Clin. Endocrinol. Metab., 2014; 99: 3821–3828
  Google Scholar
• 16. Goodman N., Guay A., Dandona P., Dhindsa S., Faiman C., CunninghamG.R., AACE Reproductive Endocrinology Scientific Committee:American Association of Clinical Endocrinologists andAmerican College of Endocrinology position statement on the associationof testosterone and cardiovascular risk. Endocr. Pract.,2015; 21: 1066–1073
  Google Scholar
• 17. Halabi S., Collins E.G., Thorevska N., Tobin M.J., Laghi F.: Relationshipbetween depressive symptoms and hypogonadism in menwith COPD. COPD, 2011; 8: 346–353
  Google Scholar
• 18. Hall S.A., Esche G.R., Araujo A.B., Travison T.G., Clark R.V., WilliamsR.E., McKinlay J.B.: Correlates of low testosterone and symptomaticandrogen deficiency in a population-based sample. J. Clin.Endocrinol. Metab., 2008; 93: 3870–3877
  Google Scholar
• 19. Isidori A.M., Buvat J., Corona G., Goldstein I., Jannini E.A., LenziA., Porst H., Salonia A., Traish A.M., Maggi M.: A critical analysis ofthe role of testosterone in erectile function: From pathophysiologyto treatment – A systematic review. Eur. Urol., 2014; 65: 99–112
  Google Scholar
• 20. Jones T.H., Arver S., Behre H.M., Buvat J., Meuleman E., MoncadaI., Morales A.M., Volterrani M., Yellowlees A., Howell J.D., ChannerK.S., TIMES2 Investigators.: Testosterone replacement in hypogonadalmen with type 2 diabetes and/or metabolic syndrome (theTIMES2 study). Diabetes Care, 2011; 34: 828–837
  Google Scholar
• 21. Kamischke A., Kemper D.E., Castel M.A., Lüthke M., Rolf C.,Behre H.M., Magnussen H., Nieschlag E.: Testosterone levels in menwith chronic obstructive pulmonary disease with or without glucocorticoidtherapy. Eur. Respir. J., 1998; 11: 41–45
  Google Scholar
• 22. Kaplan S.A., Lee J.Y., O’Neill E.A., Meehan A.G., Kusek J.W.: Prevalenceof low testosterone and its relationship to body mass indexin older men with lower urinary tract symptoms associated withbenign prostatic hyperplasia. Aging Male, 2013; 16: 169–172
  Google Scholar
• 23. Kelsey T.W., Li L.Q., Mitchell R.T., Whelan A., Anderson R.A.,Wallace W.H.: A validated age-related normative model for maletotal testosterone shows increasing variance but no decline afterage 40 years. PLoS One, 2014; 9: e109346
  Google Scholar
• 24. Kohn T.P., Louis M.R., Pickett S.M., Lindgren M.C., Kohn J.R., PastuszakA.W., Lipshultz L.I.: Age and duration of testosterone therapypredict time to return of sperm count after human chorionic gonadotropintherapy. Fertil. Steril., 2017; 107: 351–357
  Google Scholar
• 25. Malkin C.J., Pugh P.J., West J.N., van Beek E.J., Jones T.H., ChannerK.S.: Testosterone therapy in men with moderate severity heartfailure: A double-blind randomized placebo controlled trial. Eur.Heart J., 2006; 27: 57–64
  Google Scholar
• 26. Martens H.F., Sheets P.K., Tenover J.S., Dugowson C.E., BremnerW.J., Starkebaum G.: Decreased testosterone levels in men withrheumatoid arthritis: Effect of low dose prednisone therapy. J. Rheumatol.,1994; 21: 1427–1431
  Google Scholar
• 27. Mateo L., Nolla J.M., Bonnin M.R., Navarro M.A., Roig-EscofetD.: Sex hormone status and bone mineral density in men withrheumatoid arthritis. J. Rheumatol., 1995; 22: 1455–1460
  Google Scholar
• 28. Mazzola C.R., Katz D.J., Loghmanieh N., Nelson C.J., MulhallJ.P..: Predicting biochemical response to clomiphene citrate in menwith hypogonadism. J. Sex. Med. 2014; 11: 2302–2307
  Google Scholar
• 29. Morgentaler A., Miner M.M., Caliber M., Guay A.T., Khera M.,Traish A.M.: Testosterone therapy and cardiovascular risk: Advancesand controversies. Mayo Clin. Proc., 2015; 90: 224–251
  Google Scholar
• 30. Morgentaler A., Zitzmann M., Traish A.M., Fox A.W., JonesT.H., Maggi M., Arver S., Aversa A., Chan J.C., Dobs A.S., HackettG.I., Hellstrom W.J., Lim P., Lunenfeld B., Mskhalaya G. i wsp.: Fundamentalconcepts regarding testosterone deficiency and treatment:International expert consensus resolutions. Mayo ClinicProc., 2016; 91: 881–896
  Google Scholar
• 31. Moskovic D.J., Araujo A.B., Lipshultz L.I., Khera M.: The 20-yearpublic health impact and direct cost of testosterone deficiency inU.S. men. J. Sex. Med., 2013; 10: 562–569
  Google Scholar
• 32. Mulhall J.P., Trost L.W., Brannigan R.E., Kurtz E.G., Redmon J.B.,Chiles K.A., Lightner D.J., Miner M.M., Murad M.H., Nelson C.J., PlatzE.A., Ramanathan L.V., Lewis R.W.: Evaluation and management oftestosterone deficiency: AUA guideline. J. Urol., 2018; 200: 423–432
  Google Scholar
• 33. Mulligan T., Frick M.F., Zuraw Q.C., Stemhagen A., McWhirterC.: Prevalence of hypogonadism in males aged at least 45 years:The HIM study. Int. J. Clin. Pract., 2006; 60: 762–769
  Google Scholar
• 34. Muraleedharan V., Marsh H., Kapoor D., Channer K.S., JonesT.H..: Testosterone deficiency is associated with increased riskof mortality and testosterone replacement improves survival inmen with type 2 diabetes. Eur. J. Endocrinol., 2013; 169: 725–733
  Google Scholar
• 35. Nieschlag E., Bouloux P.G., Stegmann B.J., Shankar R.R., GuanY., Tzontcheva A., McCrary Sisk C., Behre H.M.: An open-label clinicaltrial to investigate the efficacy and safety of corifollitropin alfacombined with hCG in adult men with hypogonadotropic hypogonadism.Reprod. Biol. Endocrinol., 2017; 15: 17
  Google Scholar
• 36. Nieschlag E., Swerdloff R., Behre H.M., Gooren L.J., KaufmanJ.M., Legros J.J., Lunenfeld B., Morley J.E., Schulman C., Wang C.,Weidner W., Wu F.C.: Investigation, treatment and monitoring oflate-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations.Int. J. Androl., 2005; 28: 125–127
  Google Scholar
• 37. Ohlander S.J., Varghese B., Pastuszak A.: Erythrocytosis followingtestosterone therapy. Sex. Med. Rev., 2017; 61: 1038–1045
  Google Scholar
• 38. Pastuszak A.W., Badhiwala N., Lipshultz L.I. Khera M.: Depressionis correlated with the psychological and physical aspects ofsexual dysfunction in men. Int. J. Impot. Res., 2013; 25: 194–199
  Google Scholar
• 39. Pugh P.J., Jones R.D., West J.N., Jones T.H., Channer K.S.: Testosteronetreatment for men with chronic heart failure. Heart,2004; 90: 446–447
  Google Scholar
• 40. Ramasamy R., Scovell J.M., Kovac J.R., Lipshultz L.I.: Testosteronesupplementation versus clomiphene citrate for hypogonadism:An age matched comparison of satisfaction and efficacy. J. Urol.,2014; 192: 875–879
  Google Scholar
• 41. Rao P.M., Kelly D.M., Jones T.H.: Testosterone and insulin resistancein the metabolic syndrome and T2DM in men. Nat. Rev.Endocrinol., 2013; 9: 479–493
  Google Scholar
• 42. Roberts C.K, Chen B.H., Pruthi S., Lee M.L.: Effects of varyingdoses of testosterone on atherogenic markers in healthy youngerand older men. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2014;306: R118–R123
  Google Scholar
• 43. Saad F., Aversa A., Isidori A.M., Zafalon L., Zitzmann M., GoorenL.: Onset of effects of testosterone treatment and time span untilmaximum effects are achieved. Eur. J. Endocrinol., 2011; 165:675–685
  Google Scholar
• 44. Santos M.R., Sayegh A.L., Groehs R.V., Fonseca G., TrombettaI.C., Barretto A.C., Arap M.A., Negrão C.E., Middlekauff H.R., AlvesM.J.: Testosterone deficiency increases hospital readmission andmortality rates in male patients with heart failure. Arq. Bras. Cardiol.,2015; 105: 256–264
  Google Scholar
• 45. Sato Y., Tanda H., Kato S., Onishi S., Nakajima H., Nanbu A.,Nitta T., Koroku M., Akagashi K., Hanzawa T.: Prevalence of majordepressive disorder in self-referred patients in a late onset hypogonadismclinic. Int. J. Impot. Res., 2007; 19: 407–410
  Google Scholar
• 46. Sharma R., Oni O.A., Chen G., Sharma M., Dawn B., Sharma R.,Parashara D., Savin V.J., Barua R.S., Gupta K.: Association betweentestosterone replacement therapy and the incidence of DVT andpulmonary embolism: A retrospective cohort study of the veteransadministration database. Chest, 2016; 150: 563–571
  Google Scholar
• 47. Stanworth R.D., Akhtar S., Channer K.S., Jones T.H.: The roleof androgen receptor CAG repeat polymorphism and other factorswhich affect the clinical response to testosterone replacement inmetabolic syndrome and type 2 diabetes: TIMES2 sub-study. Eur.J. Endocrinol., 2013; 170: 193–200
  Google Scholar
• 48. Sussman E.M., Chudnovsky A., Niederberger C.S.: Hormonalevaluation of the infertile male: Has it evolved? Urol. Clin. NorthAm., 2008; 35: 147–155
  Google Scholar
• 49. Taylor F., Levine L.: Clomiphene citrate and testosterone gelreplacement therapy for male hypogonadism: Efficacy and treatmentcost. J. Sex. Med., 2010; 7: 269–276
  Google Scholar
• 50. Vandenput L., Mellström D., Karlsson M.K., Orwoll E., Labrie F.,Ljunggren Ö., Ohlsson C.: Serum estradiol is associated with leanmass in elderly Swedish men. Eur. J. Endocrinol., 2010; 162: 737–745
  Google Scholar
• 51. Vigen R., O’Donnell C.I., Barón A.E., Grunwald G.K., MaddoxT.M., Bradley S.M., Barqawi A., Woning G., Wierman M.E., PlomondonM.E., Rumsfeld J.S., Ho P.M.: Association of testosteronetherapy with mortality, myocardial infarction, and stroke in menwith low testosterone levels. JAMA, 2013; 310: 1829–1836
  Google Scholar
• 52. Wang C., Nieschlag E., Swerdloff R., Behre H.M., HellstromW.J., Gooren L.J., Kaufman J.M., Legros J.J., Lunenfeld B., MoralesA., Morley J.E., Schulman C., Thompson I.M., Weidner W., Wu F.C.i wsp.: Investigation, treatment, and monitoring of late-onset hypogonadismin males: ISA, ISSAM, EAU, EAA, and ASA recommendations.Eur. Urol., 2009; 55: 121–130
  Google Scholar
• 53. Wenker E.P., Dupree J.M., Langille G.M., Kovac J., Ramasamy R.,Lamb D., Mills J.N., Lipshultz L.I.: The use of HCG-based combinationtherapy for recovery of spermatogenesis after testosteroneuse. J. Sex. Med., 2015; 12: 1334–1337
  Google Scholar
• 54. Wiehle R., Cunningham G.R., Pitteloud N., Wike J., Hsu K.,Fontenot G.K., Rosner M., Dwyer A., Podolski J.: Testosterone restorationusing enclomiphene citrate in men with secondary hypogonadism:Pharmacodynamics and pharmacokinetics. BJU Int.,2013; 112: 1188–1200
  Google Scholar
• 55. Wiehle R.D., Fontenot G.K., Michael M.S., Willett M.S., GarciaW.D., Podolski J.S.: Enclomiphene citrate stimulates serum testosteronein men with low testosterone within 14 days. J. Men’sHealth, 2014; 11: 196–205
  Google Scholar
• 56. Wiehle R.D., Fontenot G.K., Wike J., Hsu K., Nydell J., LipshultzL., ZA-203 Clinical Study Group: Enclomiphene citrate stimulatestestosterone production while preventing oligospermia: A randomized phase II clinical trial comparing topical testosterone.Fertil. Steril., 2014; 102: 720–727
  Google Scholar
• 57. World Health Organization Task Force on Methods for theRegulation of Male Fertility: Contraceptive efficacy of testosteroneinducedazoospermia and oligozoospermia in normal men. Fertil.Steril., 1996; 65: 821–829
  Google Scholar
• 58. Wu F.C., Tajar A., Beynon J.M., Pye S.R., Silman A.J., Finn J.D.,O’Neill T.W., Bartfai G., Casanueva F.F., Forti G., Giwercman A., HanT.S., Kula K., Lean M.E., Pendleton N. i wsp.: Identification of lateonsethypogonadism in middle-aged and elderly men. N. Engl. J.Med., 2010; 363: 123–135
  Google Scholar
• 59. Xu L., Freeman G., Cowling B.J., Schooling C.M.: Testosteronetherapy and cardiovascular events among men: A systematic reviewand meta-analysis of placebo-controlled randomized trials.BMC Med., 2013; 11: 108
  Google Scholar
• 60. Zitzmann M., Mattern A., Hanisch J., Gooren L., Jones H., MaggiM.: IPASS: A study on the tolerability and effectiveness of injectabletestosterone undecanoate for the treatment of male hypogonadismin a worldwide sample of 1,438 men. J. Sex. Med., 2013; 10: 579–588
  Google Scholar

Full text